Nunes AP, et al. - This study used real-world electronic health record (EHR) data to test exenatide once weekly (EQW) for overall efficacy and tolerability in racial/ethnically diverse patients with type 2 diabetes and results were also compared with those who received basal insulin (BI), taking into account race. Findings revealed that treatment with EQW versus BI was related to larger reductions in HbA1c and weight and reduced risk of hypoglycemia. Notably, these effects did not vary between white and African American patients.